Equities research analysts expect that MEDNAX Inc (NYSE:MD) will post earnings of $0.50 per share for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for MEDNAX’s earnings. The highest EPS estimate is $0.84 and the lowest is ($0.13). MEDNAX posted earnings per share of $0.89 in the same quarter last year, which suggests a negative year-over-year growth rate of 43.8%. The business is expected to announce its next earnings report on Thursday, August 6th.

According to Zacks, analysts expect that MEDNAX will report full-year earnings of $2.25 per share for the current year, with EPS estimates ranging from $1.49 to $2.84. For the next year, analysts anticipate that the business will post earnings of $2.81 per share, with EPS estimates ranging from $2.00 to $3.36. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover MEDNAX.

MEDNAX (NYSE:MD) last issued its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.52 by ($0.20). MEDNAX had a positive return on equity of 12.72% and a negative net margin of 36.30%. The firm had revenue of $846.00 million during the quarter, compared to the consensus estimate of $850.88 million. During the same period last year, the firm posted $0.71 earnings per share. The company’s revenue for the quarter was down .6% compared to the same quarter last year.

Several equities analysts recently issued reports on the company. SunTrust Banks upped their target price on MEDNAX from $15.00 to $17.00 and gave the company a “hold” rating in a research report on Thursday. JPMorgan Chase & Co. cut their price target on shares of MEDNAX from $33.00 to $20.00 and set a “neutral” rating for the company in a report on Monday, February 24th. Citigroup decreased their price target on shares of MEDNAX from $29.00 to $23.00 and set a “neutral” rating for the company in a research report on Friday, February 21st. ValuEngine cut shares of MEDNAX from a “sell” rating to a “strong sell” rating in a research report on Friday, March 20th. Finally, Zacks Investment Research upgraded shares of MEDNAX from a “sell” rating to a “hold” rating and set a $12.00 price target on the stock in a research note on Wednesday, April 8th. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and two have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $19.08.

A number of large investors have recently added to or reduced their stakes in MD. Starboard Value LP boosted its holdings in shares of MEDNAX by 103.4% in the 1st quarter. Starboard Value LP now owns 7,890,000 shares of the company’s stock valued at $91,840,000 after buying an additional 4,010,000 shares during the last quarter. ArrowMark Colorado Holdings LLC raised its stake in MEDNAX by 55.5% in the 1st quarter. ArrowMark Colorado Holdings LLC now owns 8,322,322 shares of the company’s stock valued at $96,872,000 after acquiring an additional 2,969,803 shares during the period. P2 Capital Partners LLC raised its stake in MEDNAX by 41.8% in the 4th quarter. P2 Capital Partners LLC now owns 3,900,025 shares of the company’s stock valued at $108,382,000 after acquiring an additional 1,150,025 shares during the period. Norges Bank bought a new stake in MEDNAX in the 4th quarter valued at $28,748,000. Finally, Silver Rock Financial LP bought a new stake in MEDNAX in the 1st quarter valued at $3,291,000. 89.88% of the stock is owned by hedge funds and other institutional investors.

Shares of NYSE MD traded down $0.33 during trading hours on Monday, reaching $15.17. The stock had a trading volume of 553,357 shares, compared to its average volume of 1,461,955. The business’s fifty day moving average price is $12.97 and its two-hundred day moving average price is $20.65. The company has a current ratio of 2.72, a quick ratio of 2.72 and a debt-to-equity ratio of 1.46. The firm has a market cap of $1.32 billion, a price-to-earnings ratio of -1.00, a P/E/G ratio of 0.76 and a beta of 1.40. MEDNAX has a 52-week low of $7.37 and a 52-week high of $28.66.

About MEDNAX

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.

Recommended Story: What is Forex?

Get a free copy of the Zacks research report on MEDNAX (MD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.